Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

890810C

Avanti

18:0 DDAB

Avanti Research™ - A Croda Brand 890810C

Synonyme(s) :

Dimethyldioctadecylammonium (Bromide Salt)

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C38H80NBr
Numéro CAS:
3700-67-2
Poids moléculaire :
630.95
Code UNSPSC :
12352211
Nomenclature NACRES :
NA.25

Forme

liquid

Conditionnement

pkg of 1 × 2.5 mL (890810C-25mg)
pkg of 2 × 4 mL (890810C-200mg)

Fabricant/nom de marque

Avanti Research™ - A Croda Brand 890810C

Concentration

10 mg/mL (890810C-25mg)
25 mg/mL (890810C-200mg)

Type de lipide

cationic lipids
transfection

Conditions d'expédition

dry ice

Température de stockage

−20°C

Chaîne SMILES 

CCCCCCCCCCCCCCCCCC[N+](CCCCCCCCCCCCCCCCCC)(C)C.[Br-]

InChI

1S/C38H80N.BrH/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39(3,4)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2;/h5-38H2,1-4H3;1H/q+1;/p-1

Clé InChI

PSLWZOIUBRXAQW-UHFFFAOYSA-M

Catégories apparentées

Description générale

18:0 DDAB is a cationic lipid and a quaternary ammonium salt. The hydrocarbon tails are saturated, unlike the ionizable lipids. 18:0 DDAB acts as an active nasal adjuvant.

Application

18:0 DDAB or Dimethyldioctadecylammonium (Bromide Salt) has been used to perform transfection of S2 cells.

Actions biochimiques/physiologiques

18:0 DDAB is a surface-active molecule, used as an adjuvant to induce a systemic immune response. It is non-toxic.

Conditionnement

5 mL Clear Glass Sealed Ampule (890810C-200mg)
5 mL Clear Glass Sealed Ampule (890810C-25mg)

Autres remarques

For R&D use only. Not for drug, household, or other uses.

Informations légales

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Souvent commandé avec ce produit

Réf. du produit
Description
Tarif

Pictogrammes

Skull and crossbonesHealth hazard
GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 - STOT SE 3

Organes cibles

Central nervous system, Liver,Kidney

Classe de danger pour l'eau (WGK)

WGK 3

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Sarah E McNeil et al.
Journal of pharmaceutical sciences, 100(5), 1856-1865 (2011-03-05)
The adjuvanticity of liposomes can be directed through formulation to develop a safe yet potent vaccine candidate. With the addition of the cationic lipid dimethyldioctadecylammonium bromide (DDA) to stable neutral distearoylphosphatidylcholine (DSPC):cholesterol (Chol) liposomes, vesicle size reduces while protein entrapment
Hong Yu et al.
Infection and immunity, 78(5), 2272-2282 (2010-03-17)
Major impediments to developing a Chlamydia vaccine lie in identifying immunologically relevant T-cell antigens and delivery in a manner to stimulate protective immunity. Using an immunoproteomic approach, we previously identified three immunodominant Chlamydia T-cell antigens (PmpG-1, PmpE/F-2, and RplF). Because
Ana Cristina Norberto Oliveira et al.
ACS applied materials & interfaces, 6(9), 6977-6989 (2014-04-10)
This study describes a novel liposomal formulation for siRNA delivery, based on the mixture of the neutral lipid monoolein (MO) and cationic lipids of the dioctadecyldimethylammonium (DODA) family. The cationic lipids dioctadecyldimethylammonium bromide (DODAB) and chloride (DODAC) were compared in
Anne Gallez et al.
International journal of pharmaceutics, 573, 118861-118861 (2019-11-26)
The encapsulation into liposomes of several types of molecules presents the advantages to protect the activity of these molecules and to target specific tissues. Nevertheless, a major obstacle remains the incomplete understanding of nano-bio interactions. Specifically, the impact that inclusion
Hong Yu et al.
Infection and immunity, 80(4), 1510-1518 (2012-02-01)
Major impediments to a Chlamydia vaccine lie in discovering T cell antigens and polarizing adjuvants that stimulate protective immunity. We previously reported the discovery of three T cell antigens (PmpG, PmpF, and RplF) via immunoproteomics that elicited protective immunity in
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique